
Dr. Koontz on study of dose-escalated RT plus androgen suppression in prostate cancer
“The RTOG-0815 study [of dose-escalated RT plus androgen suppression] has provided...data to have an intelligent conversation with our patients and provide them numbers so that they know what to expect,” says Bridget F. Koontz, MD.
In this video, Bridget F. Koontz, MD, provides an expert opinion on the methods and findings of the study, “Dose-escalated radiotherapy alone or in combination with short-term androgen suppression for intermediate risk prostate cancer: outcomes from the NRG Oncology/RTOG 0815 randomized trial,” presented recently at the 2021 American Society for Radiation Oncology Annual Meeting. Koontz is a radiation oncologist, US chief medical officer, and deputy global chief medical officer for GenesisCare.
Newsletter
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.


















